Concordance of claudin-18.2 expression in biopsy, resection, and recurrent specimens: implications for zolbetuximab therapy in pancreatic ductal adenocarcinoma
Daisuke Kyuno, Kazuhiko Yanazume, Akira C. Saito, Yusuke Ono, Tatsuya Ito, Masafumi Imamura, Makoto Osanai
This study evaluates the concordance of claudin-18.2 expression between biopsy, resection, and recurrent pancreatic ductal adenocarcinoma specimens, finding high agreement and supporting its use as a biomarker for zolbetuximab therapy.
Tissue Barriers · Jul 22, 2025Peer-reviewedPathology